Dezhan Health (000813): Change Of Controlling Shareholder To Kaidi Investment

Dezhan health (000813) announced on the evening of July 30 that the company recently received the decision on Issuing warning letter to Dezhan dahealth Co., Ltd., the decision on Issuing warning letter to Zhang Yong and the decision on Issuing warning letter to Du Yesong issued by Xinjiang regulatory bureau of China Securities Regulatory Commission. The warning letter points out that the company has the following information disclosure violations:

The information disclosure obligation is not fulfilled in time for the progress of major events. On December 16, 2019, the company disclosed about the capital increase of Beijing dongfanglue Biomedical Technology Co., Ltd. (hereinafter referred to as "dongfanglue") and related transactions. It plans to subscribe for 36.15 million shares of dongfanglue with cash of 300 million yuan. After the capital increase, the company holds 23.22% shares of dongfanglue, and elects the board of directors and the board of supervisors of dongfanglue, The first extraordinary general meeting of shareholders of the company in 2020 deliberated and approved the above matters, but the company did not disclose the progress of capital increase in Dongfang in time;

Information disclosure of major events is not accurate. On March 5, 2021, the company disclosed the progress of a phase III clinical trial project of DNA therapy for highly squamous intraepithelial lesions of the neck (vgx-3100 project) developed by the US partner of dongfanglue, which caused the stock price to change. On March 11, the company corrected the announcement, corrected the "subsidiary" to "participating subsidiary", and disclosed the details of the cooperation project.